Video

The Importance of Biomarker Testing for Patients and Their Families

Author(s):

Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.

Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.

Barbara Bigelow knows this well as she has been living with metastatic breast cancer since 2002. Originally told she had estrogen receptor (ER)-positive disease, she later learned she actually had triple-negative breast cancer. At the CURE® Educated Patient Breast Cancer Summit in Miami, Bigelow, who is a Metavivor board member, spoke with us about the role of biomarker testing and the concern she has for her daughters.

TRANSCRIPTION:

There’s no one breast cancer. There are many types and within that there’s several subtypes. I told you I was ER positive at one point, and I am a special person, so I mutated to triple negative. And the thing about being triple negative is it usually occurs in younger women or more in African American women, neither of which I am. And so, the biomarker testing is really important to focus in on what exactly is going on in your genetic profile and what mutations you might have that might lead us to treatment that is specifically designed for you.

You know, I happen to have a high PD-L1 marker and I also have a high tumor mutational load, and because of those two factors, they think that’s why I responded so well to the immunotherapy. Whereas, someone sitting next to me with triple-negative breast cancer might not have those factors and it won’t work for them at all.

The testing is critical. Just a month ago, I asked (my doctors) to update my testing because of my daughters. I mean, my daughters are 28 and 30 now, and I wanted them to update the testing for the sake of them because they’re at high risk having a mother and two maternal aunts with breast cancer, and also my nieces.

So, I mean, I wanted to update it for them so that in the future, they may discover things they don't yet know about the genetic component. And also, I've banked my blood so that if they make future discoveries, they can compare it to my blood and that might help my kids

Related Videos
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Related Content